High-definition Transcranial Direct Current Stimulation (HD-tDCS) in Late-life Depression (LLD)
NCT05322863, Not applicable, Unknown, The University of Hong Kong
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | High-definition Transcranial Direct Current Stimulation (HD-tDCS) in Late-life Depression (LLD) | ClinicalTrials.gov |
| NCT number | NCT05322863 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 58 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | The University of Hong Kong | ClinicalTrials.gov |
| Conditions | Depression in Old Age | ClinicalTrials.gov |
| Interventions | High-definition Transcranial Direct Current Stimulation | ClinicalTrials.gov |
| First posted | 2022-04-12 | ClinicalTrials.gov |
| Last updated | 2022-04-12 | ClinicalTrials.gov |
Registered outcomes 9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in the Depressive symptoms | Assessed at baseline, immediately after the intervention, and 4 and 12 weeks after the intervention. | the clinical response rate and the remission rate as measured with the HAM-D-17. A clinical response will be defined as a reduction of 50% or more in the HAM-D-17 score. A HAM-D-17 score of 7 or less will be used as an indicator of remission. Scores range from 0 to 52, with higher scores indicating more severe depression. | ClinicalTrials.gov |
| Secondary | Change in the Global Cognition | Assessed at baseline, immediately after the intervention, and 4 and 12 weeks after the intervention. | Using the Hong Kong Chinese version of the Montreal Cognitive Assessment. The total score ranges from 0-30 with higher scores indicating better cognition. | ClinicalTrials.gov |
| Secondary | Change in the Working Memory | Assessed at baseline, immediately after the intervention, and 4 and 12 weeks after the intervention. | Measured by forward and backward digit span. | ClinicalTrials.gov |
| Secondary | Change in the Executive Functioning | Assessed at baseline, immediately after the intervention, and 4 and 12 weeks after the intervention. | Measured by the Trail Making Test Parts A and B. | ClinicalTrials.gov |
| Secondary | Change in the Verbal Fluency | Assessed at baseline, immediately after the intervention, and 4 and 12 weeks after the intervention. | Measured by category verbal fluency test. | ClinicalTrials.gov |
| Secondary | Change in the Attention | Assessed at baseline, immediately after the intervention, and 4 and 12 weeks after the intervention. | Measured by the Stroop test. | ClinicalTrials.gov |
| Secondary | Change in the Anxiety symptoms | Assessed at baseline, immediately after the intervention, and 4 and 12 weeks after the intervention. | Measured by the Hamilton Anxiety Rating Scale (HAMA). It is a widely used clinician-rated scale ranging from 0-56, with higher marks represent more severe in anxiety symptoms. | ClinicalTrials.gov |
| Secondary | Change in Daily functioning | Assessed at baseline, immediately after the intervention, and 4 and 12 weeks after the intervention. | Instrumental activities of daily living will be assessed with the Hong Kong Chinese version of the Lawton Instrumental Activities of Daily Living Scale. The daily functioning would be assessed with a total score ranging from 0 to 27. A higher score indicates a higher functioning level. | ClinicalTrials.gov |
| Secondary | Change in Adverse effects and risk indicators | Assessed immediately after each (in total 10) individual treatment session. | checklist of potential adverse effects associated with t-DCS administration will be generated from the available literature. Risk indicators such as suicidal risk or severe self-neglect that would necessitate immediate changes to treatment will be directly assessed according to the risk and needs. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 23
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 3167442 | BACKGROUND | PubMed |
| 12182927 | BACKGROUND | PubMed |
| 12634292 | BACKGROUND | PubMed |
| 15879590 | BACKGROUND | PubMed |
| 16135616 | BACKGROUND | PubMed |
| 16582045 | BACKGROUND | PubMed |
| 20434997 | RESULT | PubMed |
| 21665534 | RESULT | PubMed |
| 21840287 | RESULT | PubMed |
| 22104190 | RESULT | PubMed |
| 22236735 | BACKGROUND | PubMed |
| 23149292 | BACKGROUND | PubMed |
| 23615118 | RESULT | PubMed |
| 23759278 | BACKGROUND | PubMed |
| 25179996 | RESULT | PubMed |
| 26329381 | RESULT | PubMed |
| 27056623 | RESULT | PubMed |
| 27223853 | BACKGROUND | PubMed |
| 27965533 | RESULT | PubMed |
| 29111077 | RESULT | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 5
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Digit Span Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)